華潤醫藥(03320.HK)斥9,344萬元人幣增持英特集團(000411.SZ)
華潤醫藥(03320.HK)公布,間接全資附屬公司華潤醫藥商業分別以大約7,528.87萬元人民幣(下同)及1,814.67萬元,從浙江省中醫藥健康產業集團有限公司及浙江華辰投資發展有限公司收購其英特集團(000411.SZ)668.64萬股及161.16萬股,每股價格為11.26元。
華潤醫藥商業目前合共持有英特集團股份4,978.8萬股,佔英特集團增發之後的總股本之20%。
公司認為英特集團作為浙江省醫藥流通行業區域龍頭企業之一,具備良好的業務基礎及合作平台,華潤醫藥商業可借助雙方未來的戰略合作,充分實現優勢互補及強強聯合及全面提升華潤醫藥商業的運作效率以及競爭能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.